Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:26 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 8,039 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Completed Phase 1 Interventional

Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine in HIV Positive, Asymptomatic and Symptomatic Individuals

NCT00000664
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 1 Interventional

A Study of AL721 in HIV-Infected Patients With Swollen Lymph Nodes

NCT00001012
View directory record Official record
Conditions
HIV Infections
Interventions
AL 721
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • New Orleans, Louisiana • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Nov 3, 2026, 11:26 AM EST
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04732871
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
1,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 3, 2026, 11:26 AM EST
Approved For Marketing No phase listed Expanded access

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

NCT00097799
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir, Ritonavir
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Timeline
Started 2004
U.S. locations
115
States / cities
Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Pregnant Women From Infectious Diseases

NCT01761799
View directory record Official record
Conditions
Influenza, Pertussis
Interventions
P3 Vaccine Promotion Package.
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
11
States / cities
Athens, Georgia • Atlanta, Georgia • Bogart, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Nov 3, 2026, 11:26 AM EST
Completed No phase listed Observational

Preop COVID Testing Patterns

NCT04838119
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
375,692 participants
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Phase 3 Interventional Results available

Losmapimod Safety and Efficacy in COVID-19

NCT04511819
View directory record Official record
Conditions
COVID-19
Interventions
Losmapimod oral tablet, Placebo oral tablet
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Irvine, California • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 3 Interventional

Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents

NCT00075907
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz + 2 NRTIs, Lopinavir/Ritonavir + 2 NRTIs, Therapeutic Drug Monitoring
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 23 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 3 Interventional Results available

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

NCT03089944
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

NCT05894564
View directory record Official record
Conditions
Covid19
Interventions
Fluvoxamine, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
103
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

NCT03641339
View directory record Official record
Conditions
Zika, Dengue, Malaria, Chikungunya, Leishmaniasis
Interventions
One vector feeding, Four vector feeding
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional

Vitamin B Therapy for Hyperlactatemia

NCT00031057
View directory record Official record
Conditions
HIV Infections
Interventions
Thiamine hydrochloride, Riboflavin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Text-based Interventions to Promote COVID-19 Vaccinations

NCT04800965
View directory record Official record
Conditions
Covid19, Vaccines
Interventions
Patient MyChart Scheduling Link, Patient Educational Video, Enhanced Follow through Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

NCT01482767
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

NCT04392232
View directory record Official record
Conditions
Coronavirus, COVID-19, Convalescent Plasma
Interventions
Convalescent Plasma
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
16 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial

NCT03149757
View directory record Official record
Conditions
HIV Infections
Interventions
YouTHrive, Information-only Control
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 24 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 3, 2026, 11:26 AM EST
Completed Not applicable Interventional

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

NCT00100581
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV

NCT02401230
View directory record Official record
Conditions
HIV
Interventions
Truvada, Gel lubricant
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Nov 3, 2026, 11:26 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

NCT02373930
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG 50 mg, RPV 25 mg, DTG/RPV 50 mg/25 mg: Product Code AS, DTG/RPV 50 mg/25 mg: Product Code AM, DTG/RPV 50 mg/25 mg: Product Code AQ, DTG/RPV 50 mg/25 mg: Product Code AK, DTG/RPV 50 mg/25 mg: Product Code AR
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Nov 3, 2026, 11:26 AM EST
Completed No phase listed Observational

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

NCT05233592
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
CGM
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Nov 3, 2026, 11:26 AM EST
Terminated Not applicable Interventional

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

NCT01951209
View directory record Official record
Conditions
Liver Cirrhosis, Chronic Hepatitis C
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
David E. Kaplan, MD MSc
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Nov 3, 2026, 11:26 AM EST
Completed No phase listed Observational

Clinical IGSP-CHOP Boston

NCT00428831
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Nov 3, 2026, 11:26 AM EST